Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A. Fisher, K Turner, Brian Angus et al.|UCL Discovery (University College London)|2022Cited by 58
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL BlockadeMichelle M. Williams, Rebecca S. Cook, Linus Lee et al.|Molecular Cancer Research|2016Cited by 55
ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactationMichelle M. Williams, Rebecca S. Cook, David Vaught et al.|Breast Cancer Research|2017Cited by 29
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancersMichelle M. Williams, Rebecca S. Cook, Linus Lee et al.|Cell Death and Disease|2018Cited by 25
Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association StudyThomas A. Werfel, Rebecca S. Cook, Donna J. Hicks et al.|Molecular Cancer Therapeutics|2020Cited by 23